GlassScriptPhysician profile
Sarah Malik
NPI 1477819076
$4,420.66
in general payments reported to CMS, 2019-2025
19 companies · $1,478 in 2025
The $1,478 reported for 2025 was more than what 80% of Behavioral Neurology & Neuropsychiatry providers received nationally (typical 2025 total: $153).
See the full distribution for Behavioral Neurology & Neuropsychiatry
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $982 · 2020: $376 · 2021: $303 · 2022: $354 · 2023: $591 · 2024: $337 · 2025: $1,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,405.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $906.25 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $544.53 | 2020-2025 | Caplyta |
| Indivior INC. | $400.75 | 2019-2024 | Perseris |
| Neurocrine Biosciences, INC. | $374.57 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $373.00 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Lundbeck LLC | $280.69 | 2019-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $278.05 | 2019-2025 | Fanapt |
| Abbvie INC. | $273.88 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $164.43 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $154.73 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $151.95 | 2021-2025 | Uzedy, Austedo Xr |
| Idorsia Pharmaceuticals US INC | $117.37 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $110.15 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $99.12 | 2019-2024 | Trintellix |
| Allergan, INC. | $64.85 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $60.15 | 2019 | |
| Sage Therapeutics, LLC | $30.60 | 2023 | |
| Abbott Laboratories | $22.95 | 2024 | Ensite Precision |
| Acadia Pharmaceuticals INC | $12.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.